# Celldex to Present at Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/CLDX/celldex-to-present-at-upcoming-investor-conferences-b2c5a1cd
Ticker: CLDX
Company: Celldex Therapeutics
Source: Celldex Therapeutics
Published: 2026-02-09 13:01 EST
## Summary

Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the...

## Article Body
Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences:

Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 3:30 pm ET

TD Cowen 46th Annual Health Care Conference on Wednesday, March 4 at 9:10 am ET

Leerink Global Healthcare Conference on Tuesday, March 10 at 3:40 pm ET

Live webcasts of the presentations will be available on the " Events & Presentations " page of the "Investors" section of the Celldex website. Replays will be available for 90 days following the event.

About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit www.celldex.com .

Company Contact Sarah Cavanaugh Senior Vice President, Corporate Affairs & Administration (508) 864-8337 scavanaugh@celldex.com

Patrick Till Meru Advisors (484) 788-8560 ptill@meruadvisors.com
## Recent Company News
- 2026-07-21 20:01 EST — [Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis](https://biopharmsignal.com/news/CLDX/celldex-reports-results-from-phase-2-study-of-barzolvolimab-in-prurigo-nodularis-3b2fe3ca) — Source: Celldex Therapeutics
- 2026-07-15 20:01 EST — [Celldex Announces Planned Transition of Chief Financial Officer](https://biopharmsignal.com/news/CLDX/celldex-announces-planned-transition-of-chief-financial-officer-26ce0227) — Source: Celldex Therapeutics
- 2026-06-14 14:21 EST — [Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting](https://biopharmsignal.com/news/CLDX/celldex-presents-long-term-barzolvolimab-results-demonstrating-sustained-off-tre-61dd564d) — Source: Celldex Therapeutics
- 2026-06-14 09:15 EST — [Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting](https://biopharmsignal.com/news/CLDX/celldex-presents-positive-first-in-human-results-from-phase-1-study-of-novel-bis-b70274b7) — Source: Celldex Therapeutics
- 2026-06-10 20:01 EST — [Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress](https://biopharmsignal.com/news/CLDX/celldex-announces-multiple-upcoming-presentations-from-leading-mast-cell-targeti-2a9c11f3) — Source: Celldex Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)